 |
|
|
 |
|
Client
- A leading specialty pharmaceutical company
Critical Challenges
- Competing brand introduced shortly after launch negated first-mover advantage of Product B
- Overcoming ophthalmologists' hesitation to prescribe a fourth-generation fluoroquinolone due to concerns with antibiotic resistance
- Recruiting and training specialty representatives to handle three separate products
Objectives
- Launch and handle sole promotion for Product A
- Mirror client sales teams for Products B and C
Solution
- Recruit, train and deploy 98 specialty-care representatives
- Deliver promised results measured in TRx's, not just activity
Results
- Product A, launched and solely marketed by PDI, led the ophthalmic market with a 35% share
- Product A and predecessor compound, co-promoted by PDI prior to Product A launch, dominated ophthalmic market with 78% share at end of 2004
- Product B TRx's increased 130% in 8 months
- Product C TRx market share was 48% at end of 2004, versus closest competitor at 40%
- Due to PDI consistently exceeding program goals, 10% of the client's sales managers, 33% of their eye-care training managers and 45% of their sales reps were sourced from PDI
|
|
Product
Three growth-phase
eye-care products
DATA
Revenue Sources
Taking into account three products handled, PDI generated one-third of overall company revenue.
Source: Verispan. PDI data
on file.
|
 |
|
|